Avaleht › Burkitti lümfoom › Michigan
Burkitti lümfoom kliinilised uuringud osariigis Michigan
10 uuringut haiguse Burkitti lümfoom jaoks otsivad osalejaid osariigis Michigan.
Linnad osariigis Michigan
Ametlik uuringutekst (inglise keeles)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- C S Mott Children's Hospital, Ann Arbor
- Children's Hospital of Michigan, Detroit
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- ja veel 1
VärbamineFaas 2
366 Days – 46 Years · Kõik sood · Uuendatud 2. okt 2026 · NCT06124157Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- ja veel 22
VärbamineFaas 3
Vanused 18–39 · Kõik sood · Uuendatud 2. okt 2026 · NCT03150693Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- ja veel 20
VärbamineFaas 2
Vanused 18 ja vanemad · Kõik sood · Uuendatud 29. sept 2026 · NCT03739814Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- C S Mott Children's Hospital, Ann Arbor
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Bronson Methodist Hospital, Kalamazoo
VärbamineFaas 2
365 Days · Kõik sood · Uuendatud 25. sept 2026 · NCT06317662Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Corewell Health ( Site 1001), Grand Rapids
VärbamineFaas 1/2
6 Months – 25 Years · Kõik sood · Uuendatud 17. sept 2026 · NCT06395103A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- C S Mott Children's Hospital, Ann Arbor
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- Bronson Methodist Hospital, Kalamazoo
- ja veel 1
VärbamineFaas 2
Vanused 1–30 · Kõik sood · Uuendatud 1. sept 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- C S Mott Children's Hospital, Ann Arbor
- Children's Hospital of Michigan, Detroit
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
- ja veel 2
VärbamineFaas 3
365 Days – 25 Years · Kõik sood · Uuendatud 25. aug 2026 · NCT03959085Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- C.S. Mott University of Michigan, Ann Arbor
VärbamineFaas 2
Vanused 7–25 · Kõik sood · Uuendatud 19. aug 2026 · NCT05082519Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
- University of Michigan Rogel Cancer Center, Ann Arbor
VärbamineFaas 1
Vanused 18 ja vanemad · Kõik sood · Uuendatud 16. juuli 2026 · NCT07532525The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
- Helen DeVos Children's Hospital at Spectrum Health, Grand Rapids
VärbamineFaas 2
Vanused 1–25 · Kõik sood · Uuendatud 4. mai 2025 · NCT03509961Allikas ClinicalTrials.gov, andmed saadud 5. okt 2026. Igal uuringul on oma osalemiskõlblikkuse tingimused; uuringumeeskond otsustab, kes saab osaleda.